{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:14:21Z","timestamp":1762161261770,"version":"3.37.3"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T00:00:00Z","timestamp":1481500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Genzyme (US)","award":["GZ-2011-10820"],"award-info":[{"award-number":["GZ-2011-10820"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0168135","type":"journal-article","created":{"date-parts":[[2016,12,12]],"date-time":"2016-12-12T23:49:34Z","timestamp":1481586574000},"page":"e0168135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease"],"prefix":"10.1371","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6957-6284","authenticated-orcid":true,"given":"Renuka Pudi","family":"Limgala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chidima","family":"Ioanou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Plassmeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Ryherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Kozhaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Austin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cem","family":"Abidoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Unutmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oral","family":"Alpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ozlem","family":"Goker-Alpan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,12,12]]},"reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1615\/CritRevOncog.2013004503","article-title":"Immunological cells and functions in Gaucher disease","volume":"18","author":"MK Pandey","year":"2013","journal-title":"Critical reviews in oncogenesis"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/bjh.12804","article-title":"Gaucher disease: haematological presentations and complications","volume":"165","author":"AS Thomas","year":"2014","journal-title":"British journal of haematology"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1615\/CritRevOncog.2013006061","article-title":"Gaucher disease and myeloma","volume":"18","author":"R Ayto","year":"2013","journal-title":"Crit Rev Oncog"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/path.4227","article-title":"B cell lymphoma and myeloma in murine Gaucher's disease","volume":"231","author":"EV Pavlova","year":"2013","journal-title":"The Journal of pathology"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2013.09.002","article-title":"Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model","volume":"111","author":"MK Pandey","year":"2014","journal-title":"Mol Genet Metab"},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ymgme.2012.04.020","article-title":"Immunological cell type characterization and Th1-Th17 cytokine production in a mouse model of Gaucher disease","volume":"106","author":"MK Pandey","year":"2012","journal-title":"Mol Genet Metab"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/TCRM.S6955","article-title":"Optimal therapy in Gaucher disease","volume":"6","author":"O Goker-Alpan","year":"2010","journal-title":"Therapeutics and clinical risk management"},{"issue":"9","key":"ref8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","article-title":"Gaucher disease and its treatment options","volume":"47","author":"LL Bennett","year":"2013","journal-title":"The Annals of pharmacotherapy"},{"issue":"Suppl 1","key":"ref9","first-page":"82","article-title":"Management of Gaucher disease: enzyme replacement therapy","volume":"12","author":"A Zimran","year":"2014","journal-title":"Pediatric endocrinology reviews: PER"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"GM Pastores","year":"2004","journal-title":"Seminars in hematology"},{"issue":"Suppl 1","key":"ref11","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/ajh.24056","article-title":"Long-term treatment outcomes in Gaucher disease","volume":"90","author":"J Charrow","year":"2015","journal-title":"American journal of hematology"},{"issue":"12","key":"ref12","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/ajh.21280","article-title":"A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase","volume":"83","author":"N Weinreb","year":"2008","journal-title":"American journal of hematology"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/GIM.0b013e3181c39194","article-title":"A validated disease severity scoring system for adults with type 1 Gaucher disease","volume":"12","author":"NJ Weinreb","year":"2010","journal-title":"Genetics in medicine: official journal of the American College of Medical Genetics"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s13023-015-0280-3","article-title":"Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3)","volume":"10","author":"NJ Weinreb","year":"2015","journal-title":"Orphanet journal of rare diseases"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2009.07872.x","article-title":"Timing of initiation of enzyme replacement therapy after diagnosis of type 1 Gaucher disease: effect on incidence of avascular necrosis","volume":"147","author":"PK Mistry","year":"2009","journal-title":"British journal of haematology"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.20908","article-title":"Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention","volume":"82","author":"PK Mistry","year":"2007","journal-title":"American journal of hematology"},{"issue":"1\u20132","key":"ref17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0022-1759(00)00229-5","article-title":"A practical approach to multicolor flow cytometry for immunophenotyping","volume":"243","author":"N Baumgarth","year":"2000","journal-title":"Journal of immunological methods"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.bcmd.2016.02.003","article-title":"Persistent immune alterations and comorbidities in splenectomized patients with Gaucher disease","volume":"59","author":"SU S\u00f8nder","year":"2016","journal-title":"Blood Cells, Molecules, and Diseases"},{"issue":"5","key":"ref19","doi-asserted-by":"crossref","first-page":"e0126917","DOI":"10.1371\/journal.pone.0126917","article-title":"Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency","volume":"10","author":"SA Rawlings","year":"2015","journal-title":"PloS one"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"20052","DOI":"10.7448\/IAS.18.1.20052","article-title":"CD4:CD8 ratio as a frontier marker for clinical outcome, immune dysfunction and viral reservoir size in virologically suppressed HIV-positive patients","volume":"18","author":"W Lu","year":"2015","journal-title":"Journal of the International AIDS Society"},{"issue":"3","key":"ref21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1086\/499356","article-title":"Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort","volume":"42","author":"I Ratnam","year":"2006","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/S2352-3018(15)00018-1","article-title":"CD4\/CD8 ratio: an emerging biomarker for HIV","volume":"2","author":"S Serrano-Villar","year":"2015","journal-title":"The lancet HIV"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/651021","article-title":"Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection","volume":"201","author":"A El Hed","year":"2010","journal-title":"The Journal of infectious diseases"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1084\/jem.20130301","article-title":"Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids","volume":"211","author":"R Ramesh","year":"2014","journal-title":"The Journal of experimental medicine"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bcmd.2012.11.012","article-title":"Gammopathy and B lymphocyte clonality in patients with Gaucher type I disease","volume":"50","author":"P Rodic","year":"2013","journal-title":"Blood Cells Mol Dis"},{"issue":"1\u20133","key":"ref26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12026-014-8530-3","article-title":"Peripheral regulation of T cells by dendritic cells during infection","volume":"59","author":"EA Hemann","year":"2014","journal-title":"Immunol Res"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1615\/CritRevImmunol.v32.i2.30","article-title":"Crosstalk between T lymphocytes and dendritic cells","volume":"32","author":"C Hivroz","year":"2012","journal-title":"Crit Rev Immunol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.autrev.2014.10.010","article-title":"Role of dendritic cells in the initiation, progress and modulation of systemic autoimmune diseases","volume":"14","author":"JP Mackern-Oberti","year":"2015","journal-title":"Autoimmun Rev"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0168135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:21:42Z","timestamp":1589030502000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0168135"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Dardis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,12,12]]},"references-count":28,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2016,12,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0168135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,12,12]]}}}